We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $532M
1-Year Est. Return 171.17%
This Fund
S&P 500
This Quarter Est. Return
+19.45%
1 Year Est. Return
+171.17%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$532M
AUM Growth
+$53.4M
Cap. Flow
-$19.6M
Cap. Flow %
-3.69%
Top 10 Hldgs %
56.72%
Holding
51
New
10
Increased
15
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
AVLN
Avalyn Pharma
AVLN
+$48.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$32.4M
3
PBLS
Parabilis Medicines Inc
PBLS
+$22.8M
4
GILD icon
Gilead Sciences
GILD
+$13.9M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$11.2M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$46.1M
2
ASND icon
Ascendis Pharma A/S
ASND
+$22.7M
3
TERN
Terns Pharmaceuticals
TERN
+$21.6M
4
SLNO
Soleno Therapeutics
SLNO
+$19.3M
5
BSX icon
Boston Scientific
BSX
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYRA icon
51
Tyra Biosciences
TYRA
$1.71B
– –
-67,285
Closed -$2.58M
1 2
3

Similar funds

3IP
3Chopt Investment Partners Richmond, Virginia $532M AUM 35.46% 1-Year Est. Return
ICP
Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return
IA
Icon Advisers Greenwood Village, Colorado $532M AUM 56.47% 1-Year Est. Return
KM
KP Management Edina, Minnesota $532M AUM 118.04% 1-Year Est. Return
SIA
Sovereign Investment Advisors Phoenix, Arizona $533M AUM 16.78% 1-Year Est. Return
TCMX
Technology Crossover Management XI Menlo Park, California $533M AUM 42.1% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
NAMP
NorthStar Asset Management (Pennsylvania) Blue Bell, Pennsylvania $531M AUM 27.28% 1-Year Est. Return

Catalio Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Catalio Capital Management held 51 positions worth $532M, up 11% from $479M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Catalio Capital Management withdrew a net $19.6M in Q2 2026, closing 12 positions and reducing 9 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $21.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Catalio Capital Management opened a new position in Avalyn Pharma worth $55.2M.

  • Catalio Capital Management's largest Q2 2026 buy was Avalyn Pharma: 1,675,830 shares worth $55.2M.
  • Catalio Capital Management added most to Gilead Sciences in Q2 2026, an estimated $13.9M increase.
  • Catalio Capital Management's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $46.1M.
  • Catalio Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $21.6M.
  • Catalio Capital Management's ten largest holdings make up 57% of its $532M portfolio in Q2 2026.
  • Catalio Capital Management opened 10 new positions and closed 12 in Q2 2026.
  • Catalio Capital Management's portfolio value rose 11% quarter-over-quarter to $532M.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.